肾包膜下移植法预测人体肿瘤化疗药物敏感性的临床Ⅱ期试验

Phase Ⅱ Clinical Trial of the Human Tumor Sensitivity Test of Chemotherapeutic Agents by SRCA

本研究纳入可评价的病例20例,进行肾包膜下移植法预测抗肿瘤药物敏感性的临床试验.结果:选用第一敏感药物单药化疗的有效率高达42.8％.接近单药阿霉素的有效率。切取原发灶作单药的敏感性有效率为零,而切取转移性淋巴结作药敏,经单药治疗的有效率为35.2％。用过化疗的病人其有效率为40％(2/5),未用过化疗的病人则为46.1％(6/13)。测试对乳腺癌病人敏感的药物种类有ADM、CTX、MTX、DDP、VCR,证明肾包膜下移植法对肿瘤化疗选用抗癌药起到一定的指导作用。

This study evaluated results of 20 human tumor sensitivity test of chemotherapeutic agents by SRCA (Subrenal Capsule Assay). The result showed that the responsive rate with the first sensitive agent was 42. 8%. It was higher than that when the same agent was used blindly. The responsive rate in the patients who received chemotherapy previously was 40%(2/5)but that in patients who had never be treated before was 46.1%(6/13). The tested agents for patients with breast carcinoma were ADM CTX MTX DDP and VCR. The results showed that the SRCA,as a method of tumor chemotherpacutic agents sensitivity test is good and efficacious.